The use of Interferon-γ release assays for Tuberculosis Screening in International TravelersArchived
IGRAs are increasingly being considered for the diagnosis of LTBI, as a replacement to the TST, including travel medicine. As with the TST, many uncertainties remain with regard to the efficacy of the IGRAs. It is therefore essential to secure an accurate understanding of these assays‘ known efficacy, so that they be optimally used and only in context with proven effect.
Considerations relating to social distancing measures in response to COVID-19 – second update
This document aims to support public health preparedness planning and response activities based upon social distancing measures aimed at minimising the spread of COVID-19. Available in 26 languages.
Poster: COVID-19 - Plan your journey
These posters summarise the air travel experience for passengers once normal services resume following the outbreak of COVID-19, as defined in the EASA/ECDC operational guidelines.
Considerations relating to passenger locator data, entry and exit screening and health declarations in the context of COVID-19 in the EU/EEA and the UK
The scope of this document is to provide ECDC’s views on the passenger locator data required and the appropriate use of entry and exit screening procedures at points of entry (PoE), including health declaration forms, in the context of COVID-19 in the EU/EEA and the United Kingdom (UK).